Central Pharmaceutical JSC No2

Central Pharmaceutical JSC No2 FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Central Pharmaceutical JSC No2 (DP2.VN) as of Nov 22, 2026 is -15.36 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -23.06 % — a change of -33.40% (higher).

FCF Conversion

-15.36 %

YoY

-33.40%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Central Pharmaceutical JSC No2 is 2022 -15.36 % . FCF Conversion Rate (FCF/EBITDA) of Central Pharmaceutical JSC No2 was 2021 -23.06 % . It decreases by -33.40% higher compared to the previous year.

The Central Pharmaceutical JSC No2 FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
70.87 VND
Jan 1, 2017
-230,182.14 VND
Jan 1, 2018
-11.98 VND
Jan 1, 2019
7.63 VND
Jan 1, 2020
-13.54 VND
Jan 1, 2021
-23.06 VND
Jan 1, 2022
-15.36 VND
The Central Pharmaceutical JSC No2 FCF Conversion history
YEARFCF ConversionYoY
-15.36 %-33.40%
-23.06 %+70.36%
-13.54 %-277.50%
7.63 %-163.69%
-11.98 %-99.99%
-230,182.14 %-324,908.23%
70.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Central Pharmaceutical JSC No2 Stock analysis

What does Central Pharmaceutical JSC No2 do? Central Pharmaceutical JSC No2 generates revenue through manufacturing and distributing pharmaceutical products such as broad-spectrum antibiotics, tablets, liquid medicines, ointments, capsules, and topical balms. The company also engages in importing and trading medicinal materials and preparations. Its primary customers are healthcare providers and pharmacies across Vietnam, focusing on domestic markets for diversified pharmaceutical solutions. The firm operates within the pharmaceutical sector, leveraging its manufacturing capabilities to supply essential medicines. It targets healthcare institutions and retail pharmacy chains that require consistent access to a wide range of pharmaceutical products. Central Pharmaceutical JSC No2’s business model emphasizes local production and distribution to meet regional demand without relying on international markets or external partnerships. Revenue streams are derived from both product sales and import-trading activities. The company’s product portfolio includes antibiotics, dosage forms like tablets and capsules, and topical treatments such as ointments and balms. These offerings cater to the domestic Vietnamese healthcare sector, where demand for affordable and accessible medicines remains strong. Central Pharmaceutical JSC No2 is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Central Pharmaceutical JSC No2 stock

FCF Conversion Rate (FCF/EBITDA) of Central Pharmaceutical JSC No2 is -15.36 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of Central Pharmaceutical JSC No2 changed from -23.06 % to -15.36 %, representing a -33.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Central Pharmaceutical JSC No2 since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Central Pharmaceutical JSC No2 with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Central Pharmaceutical JSC No2

All Key Metrics — Central Pharmaceutical JSC No2